GoodRx CEO Wendy Barnes outlined the company's priorities at the 2025 JP Morgan Healthcare Conference in San Francisco.

BofA lowered the firm’s price target on GoodRx (GDRX) to $4.25 from $4.50 and keeps an Underperform rating on the shares after the company ...

GoodRx (NASDAQ:GDRX – Free Report) had its price objective reduced by Citigroup from $7.00 to $6.25 in a research note issued ...

KeyBanc lowered the firm’s price target on GoodRx (GDRX) to $6 from $7 and keeps an Overweight rating on the shares. The firm notes healthcare ...

At the 2025 JP Morgan Healthcare Conference, GoodRx’s recently appointed CEO Wendy Barnes highlighted the company’s strategic position to address the gaps in the US healthcare landscape.

GoodRx returned to sequential growth in subscribers in Q3, showing potential for profit improvement. Read why I upgrade GDRX ...

Analysts have set 12-month price targets for GoodRx Holdings, revealing an average target of $6.25, a high estimate of $7.00, ...

GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Free Report) dropped 8.4% during trading on Monday after Citigroup lowered their price target on the stock from $7.00 to $6.25. Citigroup currently has a buy ...

To find out whether they really work, we tried four of them—GoodRx, LowestMed, Mobile Rx Card, and WeRx—to price a month's supply of the cholesterol-lowering drug Lipitor (40 milligrams ...

The average price per insulin unit hit a 10-year low in 2024, largely driven by federal actions and voluntary price cuts from drugmakers, according to a Jan. 15 GoodRx report.